Vanda Pharmaceuticals (VNDA) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Vanda Pharmaceuticals (VNDA) closed the latest trading day at $4.06, indicating a -1.46% change from the previous session's end. This change lagged the S&P 500's daily loss of 1.2%. On the other ...

Mihael Hristos Polymeropoulos, the President and CEO of $VNDA, bought 10,000 shares of the company on 02-25-2025 for an estimated $44,640. This trade was reported by ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.04 per share a year ago.

Vandana Singh VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced that the FDA issued a complete response letter to its new ...

Hello, and thank you for standing by. At this time, I would like to welcome you to the Q4 2024 Vanda Pharmaceuticals, Inc. Earnings Conference Call. [Operator Instructions] I would now like to ...

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed ...

These seven high-quality ETFs provide current income and offer the opportunity for growth over time.